Major Depressive Disorder (MDD), a major contributor to disability and disease burden, is a critical public health issue. Typical treatments for MDD include pharmacotherapy and office-based therapy. However, fewer than 60% of those with MDD respond to a single course of these treatments, and the relapse rate is nearly 50%. In contrast, acute sleep deprivation therapy (SD) yields an antidepressant effect in < 24 hours with comparable response rates. Clinical practice has not widely adopted the use of SD due in-part to its transient effects and inconvenience to patients. This study examined the utility self-administered baseline PANAS, POMS-SF, and VAS mood measures and baseline demographics to predict a participant’s response to SD. Depressed participants (N = 37) underwent ~36 hr of sleep deprivation. An antidepressant response was defined as a ≥ 30% decrease in HDRS-NOW score from baseline to post-sleep deprivation. Odds ratios of experiencing a response were calculated utilizing univariate binary logistic regression. 64% (n = 23) of participants responded to SD. Identifying as white OR = 5.14, p = .030, 95% CI [1.19, 22.48], being employed OR = 4.53, p = .042, 95% CI [1.06, 19.41], and greater scores on the baseline PANAS positive affect scale OR = 1.30, p = .010, 95% CI [ 1.07, 1.59], were significantly associated with the odds of experiencing an antidepressant response to SD. To our knowledge, the PANAS positive affect scale has not been previously identified as a predictor of response to SD. The results of this research may be utilized to inform and ease screening for this treatment modality in the clinical and research settings.
Recommended CitationHoff, MD/MPH, Nathan; Gehrman, PhD, CBSM, Philip R.; and George, PhD, MS, Brandon, "Sleep Deprivation as a Treatment for Depression: Comparison of mood ratings and improving prediction of treatment response" (2020). Master of Public Health Capstone Presentations. Presentation 326.